Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia

1 Feb 2021

Abstract excerpt

Acute myeloid leukemia (AML) is a threatening hematological malignant disease in which new successful approaches in therapy are needed. Cyclin-dependent kinase 6 (CDK6), a regulatory enzyme of the cell cycle that plays an important role in leukemogenesis and the maintenance of leukemia stem cells (LSC), has the potential to predict the prognosis of AML. By analyzing public databases, we observed that the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Histone Deacetylase Inhibitors Research
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33597968
DOI: 10.3389/fgene.2020.600227

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid LeukemiaPMID 33597968Read ↗

Construction of an acute myeloid leukemia prognostic model based on m6A-related efferocytosis-related genesSemantic proximity Read ↗

Targeting cell cycle regulators in hematologic malignanciesSemantic proximity Read ↗

Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies—Current Understanding, (Pre-)Clinical Application and Promising ApproachesSemantic proximity Read ↗

Differential Expression and Prognostic Significance of CDK1 and CDK6 in Breast Cancer: A Multi-Omics ApproachSemantic proximity Read ↗

Targeting CDK6 in cancer: State of the art and new insightsSemantic proximity Read ↗

Construction of a novel prognostic risk model based on m6A-related miRNAs for acute myeloid leukemiaSemantic proximity Read ↗

CDK9 inhibitors in acute myeloid leukemiaSemantic proximity Read ↗

CDK12: A Potent Target and Biomarker for Human Cancer TherapySemantic proximity Read ↗

CDK6 as a key regulator of hematopoietic and leukemic stem cell activationSemantic proximity Read ↗

CDK6 Antagonizes p53-Induced Responses during Tumorigenesis.Semantic proximity Read ↗

Evaluating the prognostic value of CD56 in pediatric acute myeloid leukemia.Semantic proximity Read ↗

HDAC6—An Emerging Target Against Chronic Myeloid Leukemia?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.